Global efforts on the replacement of the in vivo rabies vaccine potency test (NIH method)
with in vitro methods for quantification of immunodominant glycoprotein (GP) in rabies …

Rabies is an endemic, fatal zoonotic disease in the developing countries. Prevention and
post-exposure therapy require safe and efficacious vaccines. The vaccine potency depends …

The potency of all modern tissue culture human rabies vaccines is measured based on the
National Institute of Health (NIH) potency test that is laborious, time-consuming, involves …

The potency of rabies vaccines, determined using the NIH mouse protection test, can be
directly correlated to the amount of rabies virus glycoprotein (RV GP) present in the vaccine …

In vitro methods for quantification of immunodominant glycoprotein in the rabies vaccine
formulations serve as good alternative to the cumbersome and variable mice potency assay …

Abstract Although the World Health Organization recommends the use of in vitro techniques
to qualify rabies vaccine lot release, very limited proposals have been made to arrive at a …

Rabies lethality is close to 100% and annually 15 million people receive post-exposure
prophylaxis. Testing for vaccines against this zoonosis should ensure its quality. A …

The potency control of rabies vaccines is routinely performed in a vaccination-challenge test
(NIH test), which induces substantial distress and suffering in laboratory mice. Although …

Replacement of the in vivo rabies vaccine potency test (NIH test) by in vitro methods had
been discussed by several researcher including WHO expert working groups. In this paper …

The NIH test is currently used to assess the potency of rabies vaccine, a key criterion for
vaccine release. This test is based on mice immunization followed by intracerebral viral …